{"id":377153,"date":"2024-04-02T14:22:05","date_gmt":"2024-04-02T12:22:05","guid":{"rendered":"https:\/\/medizinonline.com\/?p=377153"},"modified":"2024-04-02T15:16:15","modified_gmt":"2024-04-02T13:16:15","slug":"un-inhibiteur-il-17-etabli-de-longue-date-maintenant-disponible-avec-la-formulation-sans-citrate-lilly","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/un-inhibiteur-il-17-etabli-de-longue-date-maintenant-disponible-avec-la-formulation-sans-citrate-lilly\/","title":{"rendered":"Un inhibiteur IL-17 \u00e9tabli de longue date maintenant disponible avec la formulation sans citrate [1]"},"content":{"rendered":"\n<p><strong>Un inhibiteur IL-17 \u00e9tabli de longue date dans le traitement du psoriasis en plaques mod\u00e9r\u00e9 et s\u00e9v\u00e8re<\/strong> <strong>est d\u00e9sormais disponible sans citrate.<sup>1,\u00a7&nbsp;<\/sup> Gr\u00e2ce \u00e0 la nouvelle formulation, la douleur au site d&#8217;injection est significativement r\u00e9duite.<sup>2<\/sup> Important pour les d\u00e9rmatologues:<\/strong> <strong>Dans la pratique rien d&#8217;autre ne change.<\/strong><\/p>\n\n\n\n<p><strong>Profil de s\u00e9curit\u00e9 et de tol\u00e9rance bien \u00e9tabli<sup>3,4<\/sup><\/strong><\/p>\n\n\n\n<p>La nouvelle formulation de Taltz<sup>\u00ae<\/sup> renonce au citrate comme r\u00e9gulateur d&#8217;acidit\u00e9 pour le traitement des patients atteints de psoriasis.<sup>2<\/sup> La concentration du&nbsp;principe actif reste inchang\u00e9. Dans l&#8217;\u00e9tude de bio\u00e9quivalence, aucunes diff\u00e9rences pharmacodynamiques significatives n&#8217;a \u00e9t\u00e9 d\u00e9montr\u00e9es par rapport \u00e0 la formulation originale.<sup>2<\/sup><\/p>\n\n\n\n<div class=\"wp-block-media-text is-stacked-on-mobile\" style=\"grid-template-columns:20% auto\"><figure class=\"wp-block-media-text__media\"><img fetchpriority=\"high\" decoding=\"async\" width=\"539\" height=\"540\" src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2023\/09\/Icon_Liste.png\" alt=\"\" class=\"wp-image-366442 size-full\" srcset=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2023\/09\/Icon_Liste.png 539w, https:\/\/medizinonline.com\/wp-content\/uploads\/2023\/09\/Icon_Liste-80x80.png 80w, https:\/\/medizinonline.com\/wp-content\/uploads\/2023\/09\/Icon_Liste-120x120.png 120w, https:\/\/medizinonline.com\/wp-content\/uploads\/2023\/09\/Icon_Liste-90x90.png 90w, https:\/\/medizinonline.com\/wp-content\/uploads\/2023\/09\/Icon_Liste-320x320.png 320w\" sizes=\"(max-width: 539px) 100vw, 539px\" \/><\/figure><div class=\"wp-block-media-text__content\">\n<ul class=\"wp-block-list\">\n<li>Bio\u00e9quivalence d\u00e9montr\u00e9e avec la formulation originale<sup>2,a<\/sup><\/li>\n\n\n\n<li>Profil de s\u00e9curit\u00e9 identique: pas de nouveaux signaux identifi\u00e9s<sup>2,b<\/sup><\/li>\n<\/ul>\n<\/div><\/div>\n\n\n\n<p><strong>Moins de douleurs au site d&#8217;injection<sup>2<\/sup><\/strong><\/p>\n\n\n\n<p>Pour les patients trait\u00e9s qui ressentaient des douleurs pendant ou apr\u00e8s l&#8217;injection, l&#8217;utilisation sera moins douloureuse. Lors de l&#8217;\u00e9tude de la formulation sans citrate, les patients rappportaient en effet une diminution de la douleur pendant l&#8217;injection (Image&nbsp;1).<sup>2<\/sup><\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1160\" height=\"787\" data-src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2024\/03\/Citratfree_FR_Bild-1160x787.jpg\" alt=\"\" class=\"wp-image-376684 lazyload\" data-srcset=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2024\/03\/Citratfree_FR_Bild-1160x787.jpg 1160w, https:\/\/medizinonline.com\/wp-content\/uploads\/2024\/03\/Citratfree_FR_Bild-800x543.jpg 800w, https:\/\/medizinonline.com\/wp-content\/uploads\/2024\/03\/Citratfree_FR_Bild-2048x1389.jpg 2048w, https:\/\/medizinonline.com\/wp-content\/uploads\/2024\/03\/Citratfree_FR_Bild-120x81.jpg 120w, https:\/\/medizinonline.com\/wp-content\/uploads\/2024\/03\/Citratfree_FR_Bild-90x61.jpg 90w, https:\/\/medizinonline.com\/wp-content\/uploads\/2024\/03\/Citratfree_FR_Bild-320x217.jpg 320w, https:\/\/medizinonline.com\/wp-content\/uploads\/2024\/03\/Citratfree_FR_Bild-560x380.jpg 560w, https:\/\/medizinonline.com\/wp-content\/uploads\/2024\/03\/Citratfree_FR_Bild-1920x1303.jpg 1920w, https:\/\/medizinonline.com\/wp-content\/uploads\/2024\/03\/Citratfree_FR_Bild-3072x2084.jpg 3072w, https:\/\/medizinonline.com\/wp-content\/uploads\/2024\/03\/Citratfree_FR_Bild-240x163.jpg 240w, https:\/\/medizinonline.com\/wp-content\/uploads\/2024\/03\/Citratfree_FR_Bild-180x122.jpg 180w, https:\/\/medizinonline.com\/wp-content\/uploads\/2024\/03\/Citratfree_FR_Bild-640x434.jpg 640w, https:\/\/medizinonline.com\/wp-content\/uploads\/2024\/03\/Citratfree_FR_Bild-1120x760.jpg 1120w, https:\/\/medizinonline.com\/wp-content\/uploads\/2024\/03\/Citratfree_FR_Bild-1600x1086.jpg 1600w, https:\/\/medizinonline.com\/wp-content\/uploads\/2024\/03\/Citratfree_FR_Bild-2320x1574.jpg 2320w, https:\/\/medizinonline.com\/wp-content\/uploads\/2024\/03\/Citratfree_FR_Bild-scaled.jpg 2560w\" data-sizes=\"(max-width: 1160px) 100vw, 1160px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 1160px; --smush-placeholder-aspect-ratio: 1160\/787;\" \/><figcaption class=\"wp-element-caption\">Image 1: DOULEUR SUBJECTIVE RESSENTIE juste apr\u00e8s l&#8217;injection DE TALTZ\u00ae AVEC LA FORMULATION SANS CITRATE VS. FORMULATION INITIALE (N = 63 ET 61, RESPECTIVEMENT, MODIFICATION<br>VS. BASELINE, \u00c9CHELLE VISUELLE ANALOGIQUE VAS) . MODIFI\u00c9 SELON chabra et al., 2022<sup>2<\/sup><\/figcaption><\/figure>\n\n\n\n<p><strong>Pour vous, dans la pratique, cela signifie:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Principe actif identique et bio\u00e9quivalence d\u00e9montr\u00e9e avec la formulation originale<sup>2,a<\/sup><\/li>\n\n\n\n<li>Profil d&#8217;efficacit\u00e9 et de s\u00e9curit\u00e9 consistant<sup>2-4<\/sup><\/li>\n\n\n\n<li>Forme pharmaceutique, sch\u00e9ma posologique et dur\u00e9e de conservation&nbsp; inchang\u00e9s<sup>1<\/sup><\/li>\n<\/ul>\n\n\n\n<p><strong>Efficacit\u00e9<sup>3<\/sup>&nbsp;et tol\u00e9rance<sup>4<\/sup>&nbsp;d\u00e9montr\u00e9es<\/strong> <strong>dans les \u00e9tudes cliniques \u00e0 long terme<\/strong><\/p>\n\n\n\n<p>Lors du choix du traitement, les patients trait\u00e9s accordent de l&#8217;importance \u00e0 la perspective d&#8217;un succ\u00e8s th\u00e9rapeutique \u00e0 long terme.<sup>3<\/sup> L&#8217; \u00e9tude clinique \u00e0 long terme de Taltz (Ixekizumab) confirme : une efficacit\u00e9 durable sur 5 ans et un bon profil de tol\u00e9rance.<sup>2-4<\/sup><\/p>\n\n\n\n<p class=\"has-secondary-background-color has-background cnvs-block-core-paragraph-1697013367543\"><strong>Un engagement constant en dermatologie <\/strong><br><br>Avec la formulation sans citrate,<sup>2<\/sup> Lilly poursuit son engagement dans le domaine de la dermatologie et permet aux patients atteints de psoriasis d&#8217;envisager une exp\u00e9rience am\u00e9lior\u00e9e avec Taltz<sup>\u00ae<\/sup> \u2013 avec une efficacit\u00e9<sup>3<\/sup> et une tol\u00e9rance d\u00e9montr\u00e9es.<sup>4<\/sup><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><sup>\u00a7<\/sup>&nbsp;Taltz<sup>\u00ae<\/sup> est indiqu\u00e9 dans le traitement du psoriasis en plaques mod\u00e9r\u00e9 \u00e0 s\u00e9v\u00e8re chez les patients adultes, qui n\u2019ont pas r\u00e9pondu \u00e0 d\u2019autres traitements syst\u00e9miques (y compris la ciclosporine ou le m\u00e9thotrexate ou la puvath\u00e9rapie) ou qui ne peuvent pas les suivre en raison de contre-indications ou d\u2019intol\u00e9rance.<sup>1<\/sup><\/p>\n\n\n\n<p><sup>a<\/sup>&nbsp;Les r\u00e9sultats de l\u2019\u00e9tude de bio\u00e9quivalence ouverte (\u00e9tude -ID:I1F-MC-RHCU) ont montr\u00e9 la bio\u00e9quivalence entre la formulation sans citrate et la formulation originale avec un intervalle de confiance \u00e0 90% du rapport des moyennes par la m\u00e9thode des moindres carr\u00e9s pour la pharmacocin\u00e9tique et le Tmax \u00e9taient compris entre 0,8 et 1,25. Il n\u2019y a pas eu de diff\u00e9rence statistiquement significative dans l\u2019exposition \u00e0 l\u2019Ixekizumab sur la base de  la pharmacocin\u00e9tique.<sup>2<\/sup><\/p>\n\n\n\n<p><sup>b<\/sup>\u00c0 l&#8217;exception d&#8217;une moindre douleur au site d&#8217;injection avec la formulation sans citrate, le profil de s\u00e9curit\u00e9 de l&#8217;Ixekizumab est consistant dans les deux formulations.<sup>2<\/sup><br><br>Les sp\u00e9cialistes de la sant\u00e9 peuvent demander les r\u00e9f\u00e9rences aupr\u00e8s de l\u2019entreprise en tout temps.<\/p>\n\n\n\n<p>R\u00e9f\u00e9rences:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>L&#8217;information professionelle de Taltz<sup>\u00ae<\/sup>:&nbsp;<a href=\"https:\/\/www.swissmedicinfo.ch\/ShowText.aspx?textType=FI&amp;lang=DE&amp;authNr=65907\" target=\"_blank\" rel=\"noopener\">www.swissmedicinfo.ch<\/a>.<\/li>\n\n\n\n<li>Chabra S et al. Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials. Advances in Therapy. 2022;39(6):2862-2872.<\/li>\n\n\n\n<li>Blauvelt A et al. Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial. Journal of the American Academy of Dermatology. 2021;85(2):360-368.<\/li>\n\n\n\n<li>Genovese MC et al. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.&nbsp;Rheumatology (Oxford, England). 2020;59(12):3834-3844.<\/li>\n<\/ol>\n\n\n\n<p>Origine de l&#8217;image: \u00a9 istock.com\/&nbsp;<a href=\"https:\/\/www.istockphoto.com\/de\/portfolio\/GooMmnutt?mediatype=photography\" target=\"_blank\" rel=\"noopener\">GooMmnutt<\/a><\/p>\n\n\n\n<p>Publication au nom de&nbsp; Eli Lilly (Suisse) S.A.&nbsp;16, Ch. Des Coquelicots, CH-1214 Vernier \u2013 Geneva<\/p>\n\n\n\n<p>Cliquez <a href=\"https:\/\/www.swissmedicinfo.ch\/ShowText.aspx?textType=FI&amp;lang=DE&amp;authNr=65907\" target=\"_blank\" rel=\"noopener\">ici<\/a> pour acc\u00e9der \u00e0 l&#8217;information professionnelle de Taltz<sup>\u00ae<\/sup><strong><sup>&nbsp;<\/sup><\/strong>&nbsp;<\/p>\n\n\n\n<p>PP-IX-CH-1043\/03.2024<\/p>\n\n\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fun-inhibiteur-il-17-etabli-de-longue-date-maintenant-disponible-avec-la-formulation-sans-citrate-lilly%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Un inhibiteur IL-17 \u00e9tabli de longue date dans le traitement du psoriasis en plaques mod\u00e9r\u00e9 et s\u00e9v\u00e8re est d\u00e9sormais disponible sans citrate.1,\u00a7&nbsp; Gr\u00e2ce \u00e0 la nouvelle formulation, la douleur au&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fun-inhibiteur-il-17-etabli-de-longue-date-maintenant-disponible-avec-la-formulation-sans-citrate-lilly%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":17389,"featured_media":366642,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"0","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"TRAITEMENT SYST\u00c9MIQUE DU PSORIASIS EN PLAQUES","footnotes":""},"category":[11345,11549],"tags":[],"powerkit_post_featured":[],"class_list":["post-377153","post","type-post","status-publish","format-standard","has-post-thumbnail","category-contenu-des-partenaires","category-rx-fr","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-15 07:51:51","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/377153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/17389"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=377153"}],"version-history":[{"count":3,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/377153\/revisions"}],"predecessor-version":[{"id":377161,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/377153\/revisions\/377161"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/366642"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=377153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=377153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=377153"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=377153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}